GlassScriptPhysician profile
Angala Borders-Robinson
NPI 1013963768
$123,162.72
in general payments reported to CMS, 2019-2025
47 companies · $2,397 in 2025
The $2,397 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79K · 2020: $24K · 2021: $11K · 2022: $1,959 · 2023: $1,491 · 2024: $2,528 · 2025: $2,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,342 · Education: $74.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,341.94 |
| Education | $74.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $69,777.77 | 2019-2025 | |
| Acorda Therapeutics, INC | $28,371.72 | 2019-2023 | Inbrija |
| Genentech USA, INC. | $11,722.26 | 2019-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Novartis Pharmaceuticals Corporation | $5,738.00 | 2019-2025 | |
| Emd Serono, INC. | $972.34 | 2020-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $568.29 | 2021-2025 | Duopa, Qulipta |
| Pfizer INC. | $506.84 | 2023-2025 | |
| Biogen, INC. | $476.87 | 2022-2025 | Vumerity, Tysabri, Plegridy |
| Ucb, INC. | $458.05 | 2022-2025 | Rystiggo, Nayzilam, Briviact |
| Celgene Corporation | $397.29 | 2022-2025 | Zeposia |
| Lilly USA, LLC | $393.55 | 2022-2025 | Emgality, Kisunla, Amyvid |
| Eisai INC. | $375.88 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $375.58 | 2022-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $248.79 | 2022-2025 | Ingrezza, Ongentys |
| Amgen INC. | $203.65 | 2021-2025 | Uplizna |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angala Borders-Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.